

16 December 2020 EMA/565217/2020 Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 07-10 December 2020

During its December 2020 meeting, the CHMP reviewed 3 recommendations for eligibility to PRIME: 1 was granted and 2 were denied. The individual outcomes adopted this month are listed below.



## **Eligibility granted**

Name*	Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
ECT-001-CB	Advanced Therapy Medicinal Product	Oncology	Urgent allogeneic haematopoietic stem cell transplantations	Nonclinical + Clinical exploratory	SME

 $<sup>\ ^{*}</sup>$  Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.


## **Eligibility denied**


Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Chemical Medicinal Product	Endocrinology-Gynaecology- Fertility-Metabolism	Treatment of Hypoparathyroidism	Nonclinical + Clinical exploratory	SME
Biological Medicinal Product	Oncology	Treatment of genetically defined cancers (histology-independent)	Nonclinical + Clinical exploratory (early entry)	SME


SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## Cumulative overview of PRIME eligibility recommendations adopted by 10 December 2020









<sup>\*</sup> This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.